ARIAD Pharmaceuticals’ SUCCEED trial of oral ridaforolimus on the right track ARIAD Pharmaceuticals, Inc. today reported monetary results for the third quarter and nine weeks ended September 30, 2009 and provided an update on corporate developments. SUCCEED Trial Full Enrollment Anticipated at Year-End ARIAD reaffirmed that the global, Phase 3 SUCCEED trial of oral ridaforolimus in individuals with metastatic soft cells and bone sarcomas remains on track for complete enrollment around year-end 2009. The independent Data Monitoring Committee of the SUCCEED trial completed the 1st interim efficacy evaluation as specified by the analysis protocol in September of the calendar year and recommended that randomized, placebo-controlled trial continue to full patient enrollment and completion.The initial 24-month pilot phase of the task shall focus on 10,000 neuronal protein pairs. A fresh $1million imaging system–custom-designed for the project, will generate over 1,000,000 3D images occupying 1TB of storage. Evaluation using the University’s Middle for Computational Technology will reveal a network of interacting proteins within a living neuron. As the current project targets the neurons beneath the normal condition, future expansions are probable to include disease-affected states in addition to non-neuronal cells, bridging fundamental biology to advanced medicine. The new grant may also provide invaluable opportunities for undergraduate and graduate college students in the faculty of Arts and Science to work side-by-aspect with the research team on a task at the cutting edge of scientific research and development.
10 reasons why you should consume more cucumbers Considered a veggie but technically a fruit linked to melons, the cucumber is often an afterthought or garnish for some.